drugset / Trial / NCT01314105
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I, open label dose escalation study will investigate the addition of BIBF 1120 to treatment with the combination of carboplatin and Pegylated Liposomal Doxorubicin (PLD) in patients with advanced, platinum sensitive relapsed ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer.
Timeline
- Start
- 2011-03-15
- Primary completion
- 2013-07-29
- Completion
- 2016-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 100 mg | — |
| Subject | Nintedanib | Small molecule | 150 mg | — |
| Subject | Nintedanib | Small molecule | 200 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Doxorubicin | Other / unclassified | 30 mg/m2 | — |